ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 1,250 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $84.50, for a total transaction of $105,625.00. Following the completion of the transaction, the chief financial officer now directly owns 71,772 shares in the company, valued at approximately $6,064,734. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Brett Sandercock also recently made the following trade(s):
- On Monday, October 2nd, Brett Sandercock sold 1,250 shares of ResMed stock. The stock was sold at an average price of $77.05, for a total transaction of $96,312.50.
- On Friday, September 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The stock was sold at an average price of $77.56, for a total transaction of $96,950.00.
Shares of ResMed Inc. (NYSE:RMD) opened at $83.12 on Friday. The company has a market cap of $11.76 billion, a PE ratio of 28.87, a price-to-earnings-growth ratio of 1.84 and a beta of 0.79. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.86 and a current ratio of 4.72.
ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company had revenue of $523.66 million for the quarter, compared to the consensus estimate of $506.08 million. During the same quarter in the prior year, the firm earned $0.62 earnings per share. ResMed’s revenue was up 12.5% on a year-over-year basis. analysts predict that ResMed Inc. will post 3.01 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 14th. Shareholders of record on Thursday, November 9th will be given a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a yield of 1.68%. The ex-dividend date is Wednesday, November 8th. ResMed’s dividend payout ratio (DPR) is 56.68%.
Hedge funds have recently bought and sold shares of the business. YorkBridge Wealth Partners LLC increased its position in ResMed by 4.9% during the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock valued at $115,000 after acquiring an additional 69 shares during the last quarter. Creative Planning increased its position in ResMed by 97.1% during the second quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock valued at $130,000 after acquiring an additional 823 shares during the last quarter. Toronto Dominion Bank increased its position in ResMed by 12.8% during the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after acquiring an additional 197 shares during the last quarter. Huntington National Bank bought a new position in ResMed during the second quarter valued at $156,000. Finally, BB&T Investment Services Inc. bought a new position in ResMed during the second quarter valued at $214,000. Institutional investors and hedge funds own 59.66% of the company’s stock.
Several research firms have recently commented on RMD. Jefferies Group LLC reissued a “sell” rating and issued a $56.00 target price on shares of ResMed in a report on Thursday, October 12th. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a report on Friday, September 8th. Citigroup Inc raised shares of ResMed from a “neutral” rating to a “buy” rating in a report on Wednesday, August 2nd. BMO Capital Markets boosted their target price on shares of ResMed from $70.00 to $74.00 and gave the stock a “market perform” rating in a report on Friday, October 27th. Finally, Zacks Investment Research raised shares of ResMed from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a report on Thursday, October 12th. Four investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $67.57.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
What are top analysts saying about ResMed Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ResMed Inc. and related companies.